CENTOGENE Announces Voting Results of Extraordinary General Meeting
December 18 2020 - 10:02AM
Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a
commercial-stage company focused on rare diseases that transforms
real-world clinical and genetic data into actionable information
for patients, physicians and pharmaceutical companies, today
announced the voting results of the Company’s Extraordinary General
Meeting. The shareholders of the Company voted in favor of all
proposals, which included the appointments of Dr. Andrin Oswald as
Managing Director and Dr. Jonathan Sheldon as Supervisory Director,
the reappointment of Mr. Richard Stoffelen as Managing Director,
and adjustments to the compensation of the Supervisory Board.
Dr. Flemming Ornskov, Chairman of the Supervisory Board at
CENTOGENE, said, “We would like to thank our shareholders for their
support. We look forward to working with Andrin, Jonathan, and
Richard on our mission to further scale and accelerate CENTOGENE’s
growth as a leader in advancing the diagnosis and treatment of rare
diseases.”
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases
transforming real-world clinical and genetic data into actionable
information for patients, physicians, and pharmaceutical companies.
Our goal is to bring rationality to treatment decisions and to
accelerate the development of new orphan drugs by using our
extensive rare disease knowledge, including epidemiological and
clinical data, as well as innovative biomarkers. CENTOGENE has
developed a global proprietary rare disease platform based on our
real-world data repository with over 3.6 billion weighted data
points from approximately 595,000 patients representing over 120
different countries as of September 30, 2020.The Company’s platform
includes epidemiologic, phenotypic, and genetic data that reflects
a global population, and also a biobank of these patients’ blood
samples. CENTOGENE believes this represents the only platform that
comprehensively analyzes multi-level data to improve the
understanding of rare hereditary diseases, which can aid in the
identification of patients and improve our pharmaceutical partners’
ability to bring orphan drugs to the market. As of September 30,
2020, the Company collaborated with over 40 pharmaceutical partners
covering over 45 different rare diseases.
Important Notice and DisclaimerThis press
release contains statements that constitute “forward-looking
statements” as that term is defined in the United States Private
Securities Litigation Reform Act of 1995, including statements that
express the Company’s opinions, expectations, beliefs, plans,
objectives, assumptions or projections regarding future events or
future results, in contrast with statements that reflect historical
facts. Examples include discussion of our strategies, financing
plans, growth opportunities, and market growth. In some cases, you
can identify such forward-looking statements by terminology such as
“anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,”
“project” or “expect,” “may,” “will,” “would,” “could,” or
“should,” the negative of these terms or similar expressions.
Forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
the Company. However, these forward-looking statements are not a
guarantee of our performance, and you should not place undue
reliance on such statements. Forward-looking statements are subject
to many risks, uncertainties, and other variable circumstances,
such as negative worldwide economic conditions and ongoing
instability and volatility in the worldwide financial markets, the
effects of the COVID-19 pandemic on our business and results of
operations, possible changes in current and proposed legislation,
regulations and govern-mental policies, pressures from increasing
competition and consolidation in our industry, the expense and
uncertainty of regulatory approval, including from the U.S. Food
and Drug Administration, our reliance on third parties and
collaboration partners, including our ability to manage growth and
enter into new client relationships, our dependency on the rare
disease industry, our ability to manage international expansion,
our reliance on key personnel, our reliance on intellectual
property protection, fluctuations of our operating results due to
the effect of exchange rates, or other factors. Such risks and
uncertainties may cause the statements to be inaccurate and readers
are cautioned not to place undue reliance on such statements. Many
of these risks are outside of the Company’s control and could cause
its actual results to differ materially from those it thought would
occur. The forward-looking statements included in this press
release are made only as of the date hereof. The Company does not
undertake, and specifically declines, any obligation to update any
such statements or to publicly announce the results of any
revisions to any such statements to reflect future events or
developments, except as required by law.For further information,
please refer to the Risk Factors section in our Annual Report for
the year ended December 31, 2019, on Form 20-F filed with the SEC
on April 23, 2020, Form 6-K containing our financial results for
the three months ended March 31, 2020, furnished to the SEC on June
15, 2020, Form 6-K containing our financial results for the three
and nine months ended September 30, 2020, furnished to the SEC on
December 16, 2020, and other current reports and documents
furnished to or filed with the U.S. Securities and Exchange
Commission (SEC). You may get these documents by visiting EDGAR on
the SEC website at www.sec.gov.
Media Contact:
CENTOGENE
Ben Legg
Corporate Communications
press@centogene.com
FTI Consulting
Bridie Lawlor O’Boyle
+1.917.929.5684
bridie.lawlor@fticonsulting.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Sep 2023 to Sep 2024